Trial Profile

A Phase II Trial Evaluating the Efficacy of Polatuzumab Vedotin With Rituximab, Gemcitabine, Dexamethasone, and Cisplatin (PV-RGDP) Chemotherapy for Relapsed or Refractory Diffuse Large B-cell Lymphoma

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 07 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cisplatin (Primary) ; Dexamethasone (Primary) ; Gemcitabine (Primary) ; Granulocyte colony-stimulating factors (Primary) ; Hyaluronidase (Primary) ; Polatuzumab vedotin (Primary) ; Rituximab (Primary)
Indications Diffuse large B cell lymphoma
Focus Therapeutic Use

22 Jun 2023 Status changed from not yet recruiting to recruiting.
13 Jan 2023 Planned initiation date changed to 29 May 2023.
16 Dec 2022 Planned initiation date changed from 29 Nov 2022 to 29 Dec 2022.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com